Aeon Astron Europe B.V. announces the attaining of CE certificates for its tissue engineering product and bandage lens

Aeon Astron Europe B.V. (AAE) (8 April, 2008. Leiden, the Netherlands) announced today that it attained the CE certificates for its newly introduced collagen matrix and bandage lens.

The approved collagen matrix is applied to tissue repair in ophthalmology, general, plastic and dentistry surgery. By applying AAE’s collagen matrix, it can modulate the wound healing and create a physiological and regenerative growth for the new tissue. This collagen matrix is a 3-D scaffold which has10~300 m porous structure. Size and shape has ranged from small to large for different indications.

The ologen™ plano bandage lens is a large lens and with the size of 19mm diameter, ologen™ plano bandage lens can protect the surgical site after surgery or fix the thin eye dressing direct contact with the eye surface.

Since 1998, Aeon Astron Corporation has grown both in the scope of products it offers and in the area it serves. AAC product lines, ologen™ in ophthalmology, Aongen™ Dental and Aongen™ in plastic & general surgery usage .

Bio cornea and other researches:
AAE is dedicated to the sales and marketing for the products that Body Organ Biomedical Corporation (BOBC) and Aeon Astron Corporation (AAC) have developed. Currently BOBC has some projects undergoing that includes bio cornea and other devices to treat other ophthalmic disease. For this bio cornea, the in vitro result is fantastic and the animal study will be followed very soon. Patent has firstly filed to USPTO. PCT and other fillings will be submitted.

BOBC has filed four patents to USPTO, PCT and related countries. “We are also working with long effective dermal filler that most likely to be effective for 24 months” said Michael Lai, the CEO. “ Our major focus will be in ophthalmology, dental, aesthetic and plastic surgery in the coming years. The ophthalmology application covers bio cornea and other research too. For general, aesthetic and plastic surgery, dental applications, tissue repair and tissue augmentation will be the major field to work with.”

Another filed patent is drug bonding technology and device. This aims to bond or embed drug with biomaterial and uses the biomaterial as carrier for target and slow release.

For more information, please contact us.

Contact Info
PRAAE@aeonastron.net 
Tel: +31 71 3322280
Add: Niels Bohrweg 11-13, 2333 CA Leiden, The Netherlands